← Back to All Filings

Health In Tech Director Receives $20k Stock Grant

Medium SignificanceOctober 10, 2025 at 5:24:16 PM EDT

Health In Tech, Inc.

$HIT4CIK: 0002019505

Subscribe to track HIT

Premium users can add ticker alerts and receive realtime notification updates.

Filing Summary

Health In Tech Director Receives $20k Stock Grant

Company: Health In Tech, Inc. (HIT) Form: 4 | Filed: 2025-10-10 Significance: Medium

Insider: Shrestha Sanjay K Title: Director | Relationship: Director

Transaction Summary: • Grant (A): Acquired 5,730 shares at $3.49 (Value: ~$20k) on 2025-10-08. • Forfeiture (D): Disposed of 65,469 restricted shares at $0.00 on 2025-10-03. • Owned After: 68,735 shares

Key Insight: The filing shows a director receiving a new restricted stock grant while simultaneously forfeiting a larger number of previously granted shares. This likely indicates a restructuring of the director's equity compensation plan rather than a change in sentiment.

Market Context: These are non-open market transactions related to the company's equity incentive plan. The new grant continues to align the director's interests with shareholders, while the forfeiture adjusts a prior award, possibly due to vesting conditions not being met.

View Full Filing

This is PUBLIC SEC data for educational purposes. Not investment advice.

Comprehensive Analysis

SEC Filing Analysis: Health In Tech, Inc. (HIT)

Executive Summary

  • Trading Significance: Medium
  • Key Takeaway: A director of Health In Tech, Inc. was involved in two significant non-market transactions: a forfeiture of 65,469 restricted shares and a new grant of 5,730 restricted shares valued at approximately $20,000. This suggests a restructuring of the director's long-term incentive compensation rather than a direct market sentiment signal.
  • Market Impact: The impact is expected to be neutral. These are compensatory transactions, not open-market buys or sells, and do not reflect new investment decisions by the insider.

Company Information

FieldValue
CompanyHealth In Tech, Inc.
Ticker SymbolHIT
CIK0002019505
IndustryInsurance Agents Brokers & Services [6411]

Insider Information

FieldValue
NameShrestha Sanjay K
CIK0001775802
Title/Positionnull
RelationshipDirector

Transaction Details

This filing reported two distinct non-derivative transactions for the same insider.

Transaction 1: Forfeiture

FieldValue
Form Type4
Transaction Date2025-10-03
Transaction CodeD (Disposition)
Security TypeClass A Common Stock
Shares Involved65,469
Price Per Share$0.00
Total Value$0
Shares Owned After63,005
Ownership TypeDirect

Transaction 2: Grant

FieldValue
Form Type4
Transaction Date2025-10-08
Transaction CodeA (Award)
Security TypeClass A Common Stock
Shares Involved5,730
Price Per Share$3.49
Total Value$19,997.70
Shares Owned After68,735
Ownership TypeDirect

Market Impact Analysis

Stock Impact Prediction

  • Direction: Neutral
  • Reasoning: The transactions are related to the company's equity incentive plan. The grant (Code A) is a standard form of director compensation designed to align interests with shareholders. The forfeiture (Code D) is a disposition at $0, indicating shares were returned to the company, likely because vesting conditions were not met as described in the footnotes. Neither action signals a change in the director's outlook on the company's future performance via an open-market trade.

Volume & Sentiment

  • Expected Volume Impact: None. These are not open-market transactions and will not directly impact trading volume.
  • Sentiment Indicator: Neutral. While a grant is a positive alignment tool, it is offset by the forfeiture of a larger number of shares. The net event is best interpreted as an administrative adjustment to compensation.

Investment Insights

Positive Market Indicators

  • The company continues to use equity to compensate its directors, which is a standard governance practice to align interests.

Risk Factors

  • The forfeiture of a large number of shares could imply that performance or service-based vesting targets from a previous grant were not met. This may warrant further investigation into the terms of the original grant.

Key Takeaways

  1. Compensation Restructuring: The filing reflects an adjustment in the director's equity compensation, not a market-driven investment decision.
  2. Forfeiture Context: The 65,469 shares were forfeited on a pro-rata basis in connection with the issuer's annual stockholders meeting, as per footnote F1.
  3. New Grant Terms: The new grant of 5,730 restricted shares vests quarterly, subject to continuous service, providing a new retention and incentive mechanism for the director.

Contextual Analysis

Timing Significance

The transactions occurred around the company's annual stockholders' meeting on October 3, 2025. The forfeiture was explicitly tied to this event. The new grant followed shortly after, suggesting a planned annual recalibration of director compensation.

Transaction Context

  • Footnote F1: Explains the disposition of 65,469 shares as a forfeiture of restricted stock tied to the annual stockholders' meeting. This is a non-volitional disposition.
  • Footnote F2: Clarifies the acquisition of 5,730 shares is a grant of restricted stock under the company's equity plan, with a quarterly vesting schedule.
  • Footnote F3: Confirms the final ownership of 68,735 shares consists of the new restricted stock grant and the remaining common stock.

Company Context

As a company in the insurance services sector, equity-based compensation for directors is a common practice to conserve cash and incentivize oversight and governance.

Risk Assessment

Risk Level: Low

Risk Factors

  • The filing itself presents low risk to investors as it details standard corporate compensation procedures.
  • The underlying reason for the forfeiture (e.g., missed performance metrics vs. a simple plan change) is not fully detailed but is a point of interest.

Market Considerations

  • Investors should view this filing as informational regarding corporate governance and compensation structure rather than a predictive trading signal.
  • The key takeaway is the net change in the director's holdings and the terms of the new incentive shares.

IMPORTANT DISCLAIMER: This analysis is for informational purposes only and is not intended as investment advice. The information presented is based on publicly available SEC filings and should not be construed as a recommendation to buy, sell, or hold any securities. Past performance does not guarantee future results. All investments carry risk, including the potential loss of principal. Please consult with a qualified financial advisor before making any investment decisions.

Analysis generated on 2024-06-11 | Data source: SEC EDGAR

Topics:#SECFiling#InsiderTrading#HIT#HealthInTech#Form4#StockGrant#Director#Investing#StockMarket#CorporateGovernance

Get Real-Time Alerts

Join our community to receive instant notifications when high-significance filings are published

Important Disclaimer

This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.

Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.